diatrizoate (Rx)

Brand and Other Names:Cystografin

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

uretral solution

  • 30%
  • 18% (dilute)

Retrograde Cystourethrography

Instill 25-300 mL into bladder depending on age of patient and degree of bladder irritability; amounts >300 mL may be used if bladder capacity allows; best results obtained when the bladder is filled with the contrast agent

Administration

After sterile catheterization, the bladder should be filled to capacity using suitable sterile administration set; avoid using excessive pressure; presence of bladder discomfort or reflux and/or spontaneous voiding usually indicates bladder is full

Dosage Forms & Strengths

uretral solution

  • 30%
  • 18% (dilute)

Retrograde Cystourethrography

Instill 25-300 mL into bladder depending on age of patient and degree of bladder irritability; amounts >300 mL may be used if bladder capacity allows; best results obtained when the bladder is filled with the contrast agent

Administration

After sterile catheterization, the bladder should be filled to capacity using suitable sterile administration set; avoid using excessive pressure; presence of bladder discomfort or reflux and/or spontaneous voiding usually indicates bladder is full

Next:

Adverse Effects

Frequency Not Defined

Hypothyroidism or transient thyroid suppression

With intravasation of drug

  • Anaphylactoid reactions manifested as edema of the face and glottis, respiratory distress, confusion or shock that can be fatal
Previous
Next:

Warnings

Contraindications

Hypersensitivity to diatrizoate

Intravascular or intrathecal use

Cautions

Personal or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents

Iodine sensitivity

Use intravascular techniques that minimize risk for extravasation

Use caution in hepatic impairment, heart failure, hypertension, multiple myeloma, hyperthyroidism, pheochromocytoma, renal impairment, sickle cell disease, subarachnoid hemorrhage, and thromboembolism

FDA MedWatch

  • March 30, 2022: FDA recommended newborns and children aged ≤3 years have follow-up thyroid monitoring within 3 weeks after receiving iodinated contrast media (ICM) for X-rays and other medical imaging procedures
  • Published studies found underactive thyroid and temporary decreases in thyroid hormone levels were uncommon; however, if identified and treated early, future complications may be prevented
  • Appropriately monitor for signs and symptoms of hypothyroidism and decreased thyroid hormone levels following ICM exposure; consider evaluating thyroid function within 3 weeks, especially in term and preterm neonates and children with some underlying conditions
  • If thyroid dysfunction detected, treat and monitor thyroid function as needed to avoid future complications
  • Certain pediatric patients are at increased risk, including newborns or have very low birth weight, prematurity, or presence of cardiac or other conditions (eg, requiring care in neonatal or pediatric ICUs)
  • Patients with cardiac conditions may be at greatest risk since they often require high doses of contrast during invasive cardiac procedures
Previous
Next:

Pregnancy & Lactation

Pregnancy Category: C

Lactation: Excreted in breast milk, use caution

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Provides contrast enhancement of the bladder

Previous
Next:

Images

BRAND FORM. UNIT PRICE PILL IMAGE
Gastrografin oral
-
66-10 % solution
Gastrografin oral
-
66-10 % solution
MD-Gastroview oral
-
66-10 % solution

Copyright © 2010 First DataBank, Inc.

Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.